Investing.com-- Jefferies said Spyre Therapeutics remained its top pick in the small- to mid-cap biotech sector heading into 2027, lauding its pipeline of combination therapies for inflammatory bowel disease.
Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.
Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.
Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. Read more on SYRE.
Investing.com -- Spyre Therapeutics Inc (NASDAQ:SYRE) shares fell 2.9% in after-hours trading Monday following the company’s announcement of an underwritten public offering of its common stock.
Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.
Spyre Therapeutics (SYRE) stock jumps as J.P. Morgan starts coverage with an Overweight rating and a $110 target for 2027 year-end. Read more here.
Spyre Therapeutics (NasdaqGS:SYRE) reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003. The Phase 2 study delivered clinical proof-of-concept for SPY003, the firm's anti-IL-23 therapy for ulcerative colitis. Management also reported biological proof-of-concept for all three immunology mechanisms in Spyre Therapeutics' inflammatory bowel disease portfolio. The positive 12-week SKYLINE Part A results for SPY003 and Spyre's IBD mechanisms deserve to be...
On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart’s Histopathology Index score at Week 12 with a p-value below 0.0001. That result matters because it closes out a run of three straight readouts. […]
Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was […]
Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30% SPY003 was well tolerated with a safety profile consistent with the IL-23 class SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYL
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase
Scott L Burrows, Chief Financial Officer, on September 01, 2026, sold 25,732 shares in Spyre Therape
Heidy King-Jones, Chief Legal Officer and Corporate Secretary, on September 01, 2026, sold 28,399 sh
Cameron Turtle, Director, Chief Executive Officer, on September 01, 2026, sold 15,000 shares in Spyr
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event: Citi 2026 BioPharma Back to School Conference – New YorkDate:
This is the newest page. Registered accounts read further back.